How CME Has Traded Around Earnings
Over the last eight reported quarters, CME Group has beaten the consensus earnings estimate seven times, with an average earnings surprise of 1.4%. That consistency matters, but it is the post-earning price action that usually separates a tradeable edge from a headline. Across those same eight quarters, the average 5-day price move after the report is just 0.29%, classified as “flat” drift. In other words, the market has generally believed the result and not chased it meaningfully in the days that followed.
The last four reports reinforce that pattern. On 2026-07-22, CME reported $2.99 versus the $2.91 estimate, a 2.7% surprise, and the stock rose 2.04% the next day but finished with a null% change over the following five sessions. The 2026-04-22 report delivered a $3.36 actual against a $3.34 estimate, a 0.6% surprise, with the next-day move down 0.08% and a five-day drift of only 0.55%. The 2026-02-04 quarter also beat by 0.7%, with a 0.94% next-day gain and a 2.67% five-day gain. The 2025-10-22 report beat by 1.9%, rising 0.41% the next day before slipping 2.34% over the next five sessions. The range of five-day outcomes, from -2.34% to +2.67%, still averages close to zero.
Options-Flow Dynamics Into the October 28 Report
CME Group’s next scheduled earnings release is October 28, 2026, before the open, with a current consensus EPS estimate of $2.96. Heading into that report, options flow typically prices in the unofficial consensus around how large the earnings move “should” be. With a seven-out-of-eight beat record and an average surprise of just 1.4%, expectations are already compressed; the options market often prices a relatively narrow earnings straddle compared with more volatile names.
The flat 0.29% average five-day drift tells a confirming story about realized volatility. When a stock beats repeatedly but does not extend the move, much of the event premium can be paid out through the gap rather than through a sustained multi-day trend. That dynamic tends to favor post-event implied-volatility sellers and makes pre-event straddle buyers more dependent on catching the immediate gap, because follow-through has historically been limited.
What a Disciplined Trader Watches
Given this specific history, the place to focus is not whether CME will beat, but whether the market’s real expectation for size and direction is mispriced. A disciplined trader should compare at-the-money straddle pricing with the average absolute one-day move implied by recent reports. Over the last four quarters, the next-day moves ranged from -0.08% after the April report to +2.04% after the July report, so a one-standard-deviation gap is modest relative to typical index-level moves.
Useful reference levels from the current snapshot include the price at $255.31, the 50-day EMA at $254.89, and an RSI of 57.9, which is neutral and leaves room for an earnings-driven move in either direction. Watch whether the initial gap resets the stock back toward the 50-day EMA or extends away from it, and whether the five-day drift continues its historical pattern of giving back much of the first-day move.
For a deeper look at how institutions are positioned ahead of the October 28 release, including sell-side ratings, ownership shifts, and the full institutional verdict on CME Group, see the comprehensive analyst view linked below.
Frequently Asked Questions
What is CME Group's historical earnings beat rate?
Over the last eight reported quarters, CME Group beat the consensus estimate seven times, reflecting an 87.5% beat rate, with an average earnings surprise of 1.4%.
How did the stock react after CME's July 22, 2026 earnings report?
CME reported actual EPS of $2.99 versus the $2.91 estimate, a 2.7% surprise. The stock moved 2.04% higher the next trading day, and the five-day post-earnings price change was null%.
What is CME Group's next earnings date and current consensus estimate?
CME Group's next scheduled earnings release is October 28, 2026, before the market open, with a consensus EPS estimate of $2.96.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-07-22 | $2.99 | $2.91 | +2.7% | +2.04% | null% |
| 2026-04-22 | $3.36 | $3.34 | +0.6% | -0.08% | +0.55% |
| 2026-02-04 | $2.77 | $2.75 | +0.7% | +0.94% | +2.67% |
| 2025-10-22 | $2.68 | $2.63 | +1.9% | +0.41% | -2.34% |
| 2025-07-23 | $2.96 | $2.91 | +1.7% | - | - |
| 2025-04-23 | $2.8 | $2.8 | 0% | - | - |
Previous CME editions
Get the institutional verdict on CME
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CME verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.